argenx NV ADR (ARGX)vsCorMedix Inc (CRMD)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
CRMD
CorMedix Inc
$6.46
+0.62%
HEALTHCARE · Cap: $494.06M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 1259% more annual revenue ($4.24B vs $311.71M). CRMD leads profitability with a 52.3% profit margin vs 30.5%. CRMD trades at a lower P/E of 3.1x. CRMD earns a higher WallStSmart Score of 70/100 (B-).
ARGX
Buy63
out of 100
Grade: C+
CRMD
Strong Buy70
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Margin of Safety
+46.4%
Fair Value
$13.87
Current Price
$6.46
$7.41 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 67 in profit
Keeps 52 of every $100 in revenue as profit
Strong operational efficiency at 53.9%
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
3.1% revenue growth
Smaller company, higher risk/reward
Earnings declined 28.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : CRMD
The strongest argument for CRMD centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 52.3% and operating margin at 53.9%.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : CRMD
The primary concerns for CRMD are Revenue Growth, Market Cap, EPS Growth.
Key Dynamics to Monitor
ARGX profiles as a growth stock while CRMD is a value play — different risk/reward profiles.
CRMD carries more volatility with a beta of 1.42 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
CRMD scores higher overall (70/100 vs 63/100), backed by strong 52.3% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
CorMedix Inc
HEALTHCARE · BIOTECHNOLOGY · USA
CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. The company is headquartered in Berkeley Heights, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?